Argus Cognitive makes intelligent medical instruments, delivered as SaaS, regulated by the FDA.

We create software medical devices

We develop software medical devices, powered by a proprietary platform of retaskable intelligent algorithms.

Our technology comprehensively quantifies organ-level, system-level and patient-level function

This allows medical professionals to make better, more informed clinical decisions

Our products are regulated as medical devices and are delivered as software as a service

FDA agrees:
software should turn data into
information for doctors

“Artificial intelligence (AI) and machine learning (ML) technologies have the potential to transform health care by deriving new and important insights from the vast amount of data generated during the delivery of health care every day.”
AI/ML-Based Software as a Medical Device (SaMD) Action Plan

This is a new category:

Software as a Medical Device (SaMD)

We develop software medical devices, powered by intelligent algorithms. These algorithms dynamically configure in novel ways to analyze data from existing medical instruments. They generate and measure digital models of organs, systems and/or patients to provide comprehensive, quantified and clinically actionable information. Our products are regulated as medical devices, and are delivered as software as a service.

Too often medical professionals must choose between quantitative data that is limited in scope, and qualitative data that is comprehensive. Our technology delivers quantified, comprehensive information.

Autism, Cardiology and Orthopedics

are the therapy areas Argus is pursuing first

We are working with leading medical institutions to pilot our technology

We have two lead products close to market launch

They are entering the FDA approval process

Our criteria for all products:

Significant clinical need

Efficient development pathway

Superior results relative to existing tech


We have active product development programs that address a variety of important medical areas. Our first two products entering the FDA approval process are:

1. ReVISION Award-winning analysis of right ventricle mechanics to detect and predict a range of debilitating cardiac conditions, such as certain types or heart failure, pulmonary hypertension, and more.

Learn more

2. Neurora ASD a new software technique that allows researchers and therapists to easily record rich, informative ASD metrics, such as pauses in speech, repeated words, change in pitch, and more.

Learn more

Please, feel free to reach out for white papers, publication lists, demos, etc. We love partnerships.


Behavioral Health publications

  • Predicting the ADOS-2 Calibrated Severity Score From Video And Audio Analysis

    Andras Sarkany, Khaleel Kamal, Emily Dillon, Edith Ocampo, Sarely Licona, Allie Wainer, Latha Soorya, Zoltan Toser

    INSAR - International Society for Autism Research / Annual Meeting


    Ongoing strides in robust non-intrusive methods allow for the application of computational behavioral assessments in clinical settings, mitigating tedious manual coding processes. Using machine learning components, automated behavioral assessment aims to facilitate the detailed coding of naturalistic behavior (including prosody, facial landmarks, gaze, and pose estimations)...

ReVISION publications

  • ReVISION in pediatric cardiology

    Get to the heart of pediatric kidney transplant recipients: Evaluation of left- and right ventricular mechanics by three-dimensional echocardiography

    Zsuzsanna Ladányi, Adrienn Bárczi, Alexandra Fábián, Adrienn Ujvári, Orsolya Cseprekál, Éva Kis, György Sándor Reusz, Attila Kovács, Béla Merkely, and Bálint Károly Lakatos

    Frontiers in Cardiovascular Medicine


    Kidney transplantation (KTX) markedly improves prognosis in pediatric patients with end-stage kidney failure. Still, these patients have an increased risk of developing cardiovascular disease due to multiple risk factors. Three-dimensional (3D) echocardiography allows detailed assessment of the heart and may unveil distinct functional and morphological changes in this patient population that would be undetectable by conventional methods.

More cardiology publications

  • The Impact of COVID-19 on the Preparation for the Tokyo Olympics: A Comprehensive Performance Assessment of Top Swimmers

    Emese Csulak, Árpád Petrov, Tímea Kováts, Márton Tokodi, Bálint Lakatos, Attila Kovács, Levente Staub, Ferenc Imre Suhai, Erzsébet Liliána Szabó, Zsófia Dohy, Hajnalka Vágó, Dávid Becker, Veronika Müller, Nóra Sydó, and Béla Merkely

    International Journal of Environmental Research and Public Health


    Background: The Olympic preparation of athletes has been highly influenced by COVID and post-COVID syndrome. As the complex screening of athletes is essential for safe and successful sports, we aimed to repeat the 2019-year sports cardiology screening of the Olympic Swim Team before the Olympics and to compare the results of COVID and non-COVID athletes...


Argus Cognitive was founded in 2016 by computer scientists, psychologists and a medical device entrepreneur.

  • Zoltan Toser (CEO) and Andras Lorincz (CSO) are computer scientists, specializing in machine learning.

  • Mark Pollack, MD and Latha Soorya, PhD are a practicing psychiatrist and a clinical psychologist.

  • Attila Meretei, MD has been developing medical devices for almost 20 years.

Our product development team is located in Budapest, Hungary.

We maintain a symbiotic relationship with the Neural Information Processing Group at Eotvos Lorand University, Budapest, Hungary, where we can test new technologies before including them in our development pipeline.

In cardiology we closely collaborate with various researchers in the US and Europe.

We are hiring

We are always on the lookout for talented people to join our team. We have openings in the following positions:

Our team is geographically dispersed, present in four continents, so provided you have excellent communication skills, remote work is feasible. Needless to say, good English is a must.

If all this sounds interesting, or you would like more info, don't hesitate to reach out to us at


We have a lot more to say about the company and the team, the unmet need, the market, our technology and products, clinical results and regulatory plans and opportunities in other fields of medicine. If you are interested in a dialogue, collaboration or joining our team, please reach out to us. Thank you!

Zoltan Toser

CEO, Argus Cognitive, Inc.

+1 603 322 1944

Attila Meretei, MD

President, Argus Cognitive, Inc.

+1 603 400 2440

35 South Main Street, Hanover, NH 03755